- Home
- AVNT vs BBIO Comparison
AVNT vs BBIO Comparison
Compare AVNT & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVNT
- BBIO
- Stock Information
- Founded
- AVNT 1927
- BBIO 2015
- Country
- AVNT United States
- BBIO United States
- Employees
- AVNT N/A
- BBIO N/A
- Industry
- AVNT Major Chemicals
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- AVNT Industrials
- BBIO Health Care
- Exchange
- AVNT Nasdaq
- BBIO Nasdaq
- Market Cap
- AVNT 4.8B
- BBIO 5.1B
- IPO Year
- AVNT 1993
- BBIO 2019
- Fundamental
- Price
- AVNT $41.52
- BBIO $26.49
- Analyst Decision
- AVNT Strong Buy
- BBIO Strong Buy
- Analyst Count
- AVNT 5
- BBIO 13
- Target Price
- AVNT $55.50
- BBIO $47.92
- AVG Volume (30 Days)
- AVNT 610.6K
- BBIO 2.7M
- Earning Date
- AVNT 02-12-2025
- BBIO 11-12-2024
- Dividend Yield
- AVNT 2.60%
- BBIO N/A
- EPS Growth
- AVNT N/A
- BBIO N/A
- EPS
- AVNT 1.64
- BBIO N/A
- Revenue
- AVNT $3,212,900,000.00
- BBIO $217,765,000.00
- Revenue This Year
- AVNT $5.38
- BBIO $2,648.47
- Revenue Next Year
- AVNT $4.41
- BBIO N/A
- P/E Ratio
- AVNT $25.46
- BBIO N/A
- Revenue Growth
- AVNT N/A
- BBIO 2209.77
- 52 Week Low
- AVNT $35.50
- BBIO $21.62
- 52 Week High
- AVNT $54.68
- BBIO $44.32
- Technical
- Relative Strength Index (RSI)
- AVNT 17.59
- BBIO 49.05
- Support Level
- AVNT $48.91
- BBIO $25.34
- Resistance Level
- AVNT $50.83
- BBIO $28.15
- Average True Range (ATR)
- AVNT 1.25
- BBIO 1.33
- MACD
- AVNT -1.02
- BBIO -0.24
- Stochastic Oscillator
- AVNT 3.59
- BBIO 24.73
About AVNT Avient Corporation
Avient Corp manufactures and sells a variety of chemical and plastic-based products to designers and processors of plastics. The firm operates in two segments: Color, Additives and Inks, and Specialty Engineered Materials. The company's product portfolio includes concentrated color and ink blends, plastic resins, and various specialized polymer materials used in industries such as food packaging, construction, transportation, cosmetics, and healthcare. The color, additives, & ink segment and the distribution segment together generate a vast majority of revenue. More than half of the total revenue is derived from the United States.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.